Stay Updated with the Latest Alphamab Oncology 9966.HK News in Real Time
Find 9966.HK news now at Meyka AI. Stay informed with the latest Alphamab Oncology stocks updates, including price news, market analysis, and expert insights.
German Medical Conference Scheduled for June 16, 2026
Munich medical conference on tumor treatment scheduled for June 16, 2026. Oncology Center hosts professional event for healthcare practitioners.
Analyst Upgrades and Downgrades Today: Focus Stocks AAPL, INTC, NFLX, AMD, OPAD, NVCT, TFPM
Wall Street does not stop moving. Every trading day, analysts at major firms review their positions on stocks and publish fresh rating actions. These analyst upgrades and downgrades directly influence how institutional and retail investors think about a stock. When a top firm shifts its stance on a name like Apple (AAPL) or Intel (INTC),…
Ono Pharma Seeks Japan Approval for OPDIVO Thyroid Cancer Treatment, June 12
Ono Pharma seeks Japan approval for OPDIVO in unresectable anaplastic thyroid cancer after NAVIGATION trial achieved 47.6% response rate.
Alembic Pharmaceuticals Shares Jump 3% After US FDA Tentatively Approves Larotrectinib Capsules
Alembic Pharmaceuticals shares rose nearly 3% in trading after the company announced that the US Food and Drug Administration (FDA) granted tentative approval for its Larotrectinib capsules. The development marks a positive milestone for the Indian pharmaceutical company as it continues to expand its presence in the regulated US market. The announcement triggered strong investor…
Infosys Ltd Falls 2.86% to ₹1,112.50 as IT Sector Bleeds; 4baseCare Closes Series B at ₹128 Crore With Infosys Backing
Not every decline needs a single trigger. Infosys Ltd (NSE: INFY) dropped 2.86% to ₹1,112.50 on June 11, 2026, with the broader IT sector dragging peers down simultaneously. TCS fell 1.62%, HCL Technologies dropped 3.04%, and Wipro slipped 0.88% in the same session. The selloff is sector-driven, not earnings-driven. Infosys Ltd delivered $20,158 million in…
Concord Biotech Shares Jump 5.9% After US FDA Approves Tofacitinib Arthritis Drug
Shares of Concord Biotech saw strong buying interest after a key global development. The stock rose around 5.9% in recent trading sessions after news of a US FDA approval related to its Tofacitinib-based arthritis drug. The trigger is important. The US Food and Drug Administration (FDA) approval opens doors to the world’s largest pharmaceutical market….
Parabilis Medicines Targets Up to $2.3 Billion Valuation in Expanded U.S. IPO Amid Biotech Market Rally
Parabilis Medicines is aiming for a valuation of nearly $2.3 billion through an expanded U.S. initial public offering, highlighting renewed investor confidence in the biotechnology sector. The Cambridge, Massachusetts-based company increased the size of its offering as demand for biotech IPOs continues to improve following a challenging period for the industry. The company now plans…
GSK to Buy Nuvalent for $10.6 Billion, Paying $124 Per Share in All-Cash Deal
GSK has made a major move in the global pharmaceutical industry. The company has agreed to acquire Nuvalent for $10.6 billion in an all-cash deal. The offer price is $124 per share, which is about a 40% premium compared to the last closing price of Nuvalent. This is not a small deal. It is one…
GSK Plc Announces $10.6B Nuvalent Acquisition to Boost Lung Cancer Pipeline; Stock Falls 3.24%
GSK Plc moved decisively on June 9, 2026. The British drugmaker agreed to acquire US-listed cancer drug developer Nuvalent for $10.6 billion in an all-cash deal, valuing Nuvalent at approximately $124 per share, a 40% premium to its last closing price. Net of cash acquired, GSK’s actual upfront investment totals $9.4 billion. GSK Plc stock…